The quarter cleared expectations by a wide margin. Against a published pre-release estimate of roughly $405 million in revenue and $1.80 in adjusted EPS, Halozyme delivered $481.0 million and $2.28, respectively — approximately 19% and 27% above those benchmarks.
| Metric | Q2 2026 | Q2 2025 | Year-over-year / expectation |
|---|---|---|---|
| Total revenue | $481.0M | $325.7M | +48%; versus ~$405M published estimate |
| Royalty revenue | $307.7M | $205.6M | +50% |
| GAAP diluted EPS | $1.90 | $1.33 | +43% |
| Non-GAAP diluted EPS | $2.28 | $1.54 | +48%; versus ~$1.80 published estimate |
| Adjusted EBITDA | $328.8M | $225.5M | +46% |
| Cash, cash equivalents, restricted cash and marketable securities | $231.9M | $145.4M at Dec. 31, 2025 | Increased despite buybacks |
Royalty growth, not a one-off collaboration payment, powered the upside. Royalties rose to $307.7 million, led by continued uptake of partner products including VYVGART Hytrulo and DARZALEX SC, while product sales increased to $129.6 million from $81.5 million. Collaboration revenue was only $43.7 million, so the beat reflects stronger recurring commercial royalties and product sales rather than reliance on a single deal payment (Income Statement; Financial Highlights).
Management raised every major 2026 target, materially resetting the earnings bar. The midpoint increased about 6% for total revenue, 7% for royalty revenue, 8% for adjusted EBITDA and 10% for non-GAAP EPS. That is a meaningful upgrade from the prior outlook, particularly because royalty revenue — the most strategically important and recurring component — now carries a $1.220 billion to $1.245 billion forecast versus $1.130 billion to $1.170 billion previously (2026 Guidance table).
The pipeline and capital-return updates add support, but are not all new information. The Vertex, Oruka, GSK and Incyte collaborations were announced earlier in 2026, so their inclusion mainly reinforces the expanding opportunity set rather than representing fresh quarter-end upside. The $332.8 million Q2 repurchase was substantial and reduced weighted-average diluted shares to 121.2 million from 124.2 million a year earlier, while cash and marketable securities still increased to $231.9 million (Corporate Activities; Balance Sheet; EPS Reconciliation).
Net read: a broad, substantive positive surprise. The filing combines a large revenue and adjusted-EPS beat with stronger-than-expected royalty momentum and a full-year guidance raise across all key measures. Higher amortization, R&D and SG&A from the Elektrofi and Surf Bio acquisitions and $6.9 million of patent-litigation costs temper reported margins, but they do not outweigh the recurring-revenue upside (Income Statement; Adjusted EBITDA Reconciliation).
Read the original 8-K on SEC EDGAR ↗